EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)EvaluationsstudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects

Tomoki Kojima, Wei Chen, Ronald Smulders, Stephen Stanhope, Donna Kowalski iD, Nakyo Heo, Selina Moy, Amanda Goldston, David Han, Tong Zhu

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70460 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Tomoki Kojima und 9 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma, Inc., Tokyo, Japan. Hauptthemen laut MEDLINE: Cathepsins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Astellas Pharma Global Development, Inc, Astellas Pharma Global Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ASP1617 is a novel, highly selective inhibitor of cathepsin‐S, an important protease for antigen peptide loading onto major histocompatibility complex class II molecules. Preclinically, ASP1617 prevented progression of lupus‐like glomerulonephritis in an NZB/W F1 mouse model of systemic lupus erythematosus. In this double‐blind, randomized, placebo‐controlled, first‐in‐human study in healthy subjects, ASP1617 was generally well tolerated. Treatment‐emergent adverse events of rash and throat tightness were reported in two subjects receiving the highest doses of 110 mg BID in multiple ascending dose (MAD) cohorts, leading to withdrawal of ASP1617 in both subjects. Mean elimination half‐life was 10.4–15.9 h in single ascending dose (SAD) cohorts and 13.7–20.5 h in MAD cohorts. ASP1617 exposure increased slightly greater than dose proportionally between SAD cohorts and dose proportionally between MAD cohorts and was similar between Japanese and non‐Asian subjects. A high‐fat, high‐calorie meal slightly decreased peak and total exposure and delayed absorption. Both single and multiple dosing of ASP1617 led to rapid and maximal inhibition (> 80% at 3 h post‐dose) of cathepsin‐S activity as well as the downstream increase of invariant chain p10 (Lip10) in B cells, indicating target engagement. However, in all MAD cohorts, cathepsin‐S activity gradually rebounded during treatment, surpassing baseline levels after the last dose, and cathepsin‐S mass increased significantly, fivefold above baseline, and prolonged after treatment. Due to the observed safety events, induction of the cathepsin‐S target, and gradual loss of pharmacodynamic effects during repeated dosing, appropriate mitigation strategies are necessary for the further clinical development of ASP1617. Trial Registration: ClinicalTrials.gov Identifier: NCT04077879

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CathepsinsAdultFemaleHumansMaleMiddle AgedYoung AdultDose-Response Relationship, DrugDouble-Blind MethodHalf-LifeHealthy Volunteers

Stichwörter der Autor:innen

clinical trialsdrug developmenthealthy subjectsimmunologyinhibitorspharmacodynamicspharmacokineticsphase 1race

Substanzen

cathepsin SCathepsins

Autor:innen und Institutionen

  • Astellas Pharma, Inc., Tokyo, Japan.
  • Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
  • Astellas Research Institute of America, LLC, Northbrook, Illinois, USA.
  • California Clinical Trials Medical Group, Inc., Glendale, California, USA.

ORCID-Profile: Donna Kowalski

Förderung

  • Astellas Pharma Global Development, Inc
  • Astellas Pharma Global Development

Zitieren

APA

Kojima, T., Chen, W., Smulders, R., Stanhope, S., Kowalski, D., Heo, N., Moy, S., Goldston, A., Han, D., & Zhu, T. (2026). First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects. Clinical and Translational Science. https://doi.org/10.1111/cts.70460

Vancouver

Kojima T, Chen W, Smulders R, Stanhope S, Kowalski D, Heo N, et al. First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects. Clinical and Translational Science. 2026. doi:10.1111/cts.70460

BibTeX
@article{Kojima2026,
  author = {Kojima, Tomoki and Chen, Wei and Smulders, Ronald and Stanhope, Stephen and Kowalski, Donna and Heo, Nakyo and Moy, Selina and Goldston, Amanda and Han, David and Zhu, Tong},
  title = {First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70460}
}
Kostenlos starten →